KUMAMOTO University

R

研究業績RESEARCH ACHIEVEMENTS

  1. Travis Chia, Tomofumi Nakamura, Masayuki Amano, Nobutoki Takamune, Masao Matsuoka, Hirotomo Nakata

    A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsid

    Antimicrob Agents Chemother. 2021 Jul 6;AAC0103921. doi: 10.1128/AAC.01039-21. Online ahead of print.

    https://pubmed.ncbi.nlm.nih.gov/34228546/

     

  2. Sakata K, Kikuchi J, Emoto K, Kotaki T, Ota Y, Nishina N, Hanaoka H, Otomo K, Suzuki K, Kaneko Y, Takeuchi T.

    Refractory IgG4-related Pleural Disease with Chylothorax: A Case Report and Literature Review.

    Intern Med 60(13):2135-2143,2021.doi: 10.2169/internalmedicine.6313-20. Epub 2021 Feb 1.

    https://pubmed.ncbi.nlm.nih.gov/33518567/

     

  3. Bianchi G, Czarnecki PG, Ho M, Roccaro AM, Sacco A, Kawano Y, Gulla A, Samur AA, Chen T, Wen K, Tai YT, Moscvin M, Wu X, Camci-Unal G, Da Via MC, Bolli N, Sewastianik T, Carrasco RD, Ghobrial IM, Anderson KC.

    ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.

    Blood Cancer Discovery 2(4):338-353.2021. doi: 10.1158/2643-3230.BCD-20-0164. Epub 2021 Apr 10.

    https://pubmed.ncbi.nlm.nih.gov/34238761/

     

  4. Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S.

    Prophylactic antiviral therapy for HBsAg-positive patients with DLBCL treated with rituximab-containing chemotherapy.

    Cancer Sci 112(5):1943-1954,2021. doi: 10.1111/cas.14846. Epub 2021 Mar 18.

    https://pubmed.ncbi.nlm.nih.gov/33576088/

     

  5. Shen YJ, Mishima Y, Shi J, Pistofidis RS, Redd R, Moschetta M, Manier S, Roccaro A, Sacco A, Tai YT, Mercier F, Kawano Y, Su N, Berrios B, Doench J, Root D, Michor F, Scadden D, Ghobrial IM.

    Progression signature underlies clonal evolution and dissemination of multiple myeloma.

    Blood 137(17):2360-2372,2021. doi: 10.1182/blood.2020005885.

    https://pubmed.ncbi.nlm.nih.gov/33150374/

     

     

  6. Guangyong Ma, Jun-ichirou Yasunaga, Kazuya Shimurab, Keiko Takemotob, Miho Watanabec, Masayuki Amano, Hirotomo Nakata, Benquan Liua, Xiaorui Zuoa, and Masao Matsuoka

    Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence

    Proc Natl Acad Sci U S A.2021 Apr 27;118(17):e2014783118. doi: 10.1073/pnas.2014783118.

    https://pubmed.ncbi.nlm.nih.gov/33875584/

     

     

  7. Ishihara A, Yamauchi T, Ikeda K, Fukuyoshi Y, Yokoyama T, Yonemura Y, Uchiba M, Matsui H.

    Glycosylated ferritin as an improved marker for post-transfusion iron overload.

    Int J Hematol 113(4): 537-546,2021. doi: 10.1007/s12185-020-03056-9. Epub 2021 Jan 5.

    https://pubmed.ncbi.nlm.nih.gov/33400141/

     

  8. Ishihara A, Yamauchi T, Ikeda K, Fukuyoshi Y, Yokoyama T, Yonemura Y, Uchiba M, Matsui H

    Glycosylated ferritin as an improved marker for post-transfusion iron overload.

    Int J Hematol 113(4): 537-546,2021.  doi: 10.1007/s12185-020-03056-9. Epub 2021 Jan 5.

    https://pubmed.ncbi.nlm.nih.gov/33400141/

     

     

  9. Huang J, Gou H, Yao J, Yi K, Jin Z, Matsuoka M and Zhao T

    The noncanonical role of EZH2 in cancer.

    Cancer Sci 112(4):1376-1382. doi: 10.1111/cas.14840. Epub 2021 Feb 24.

    https://pubmed.ncbi.nlm.nih.gov/33615636/

     

  10. Penova M, Kawaguchi S, Yasunaga JI, Kawaguchi T, Sato T, Takahashi M, Shimizu M, Saito M, Tsukasaki K, Nakagawa M, Takenouchi N, Hara H, Matsuura E, Nozuma S, Takashima H, Izumo S, Watanabe T, Uchimaru K, Iwanaga M, Utsunomiya A, Tabara Y, Paul R, Yamano Y, Matsuoka M and Matsuda F.

    HTLV-1 associated myelopathy/tropical spastic paraparesis in the Japanese population – a genome-wide association study.

     Proc Natl Acad Sci USA 118(11):e2004199118. doi: 10.1073/pnas.2004199118.

    https://pubmed.ncbi.nlm.nih.gov/33649182/

     

  11. Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I, Imaizumi Y, Tokunaga T, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiyo Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H Japan Clinical Oncology Group.

    A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.

    Blood Adv 5(4):984-993,2021. doi: 10.1182/bloodadvances.2020002567.

    https://pubmed.ncbi.nlm.nih.gov/33591324/

     

  12. Izaki M, Yasunaga JI, Nosaka K, Sugata K, Utsunomiya H, Suehiro Y, Shichijo T, Yamada A, Sugawara Y, Hibi T, Inomata Y, Akari H, Melamed A, Bangham C, Matsuoka M.

    In vivo dynamics and adaptation of HTV-1-infected clones under different clinical conditions

    PLOS Pathogens.2021 Feb 1;17(2):e1009271. doi: 10.1371/journal.ppat.1009271. Online ahead of print .PMID: 33524072

    https://pubmed.ncbi.nlm.nih.gov/33524072/

     

  13. Nozaki K, Maruyama D, Maeshima AM, Tajima K, Itami J, Shichijo T, Yuda S, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Izutsu K and Tobinai K.

    The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.

    Eur J Haematol 106(2): 213-220. doi: 10.1111/ejh.13539. Epub 2020 Nov 6.

    https://pubmed.ncbi.nlm.nih.gov/33098704/

     

     

  14. Nozaki K, Maruyama D, Maeshima AM, Tajima K, Itami J, Shichijo T, Yuda S, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Izutsu K and Tobinai K.

    The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.

    Eur J Haematol 106(2): 213-220,2021. doi: 10.1111/ejh.13539. Epub 2020 Nov 6.

    https://pubmed.ncbi.nlm.nih.gov/33098704/

     

  15. Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi K, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Enokitani K, Matsuda A, Ozawa K, Mitani K, Lee JW, Nakao S.

    Efficacy and safety of romiplostim refractory aplastic anemia: a phase 2/3, multicentre, open-label study.

    Brit J Haematol 192(1):190-199,2021. doi: 10.1111/bjh.17190. Epub 2020 Nov 5.

    https://pubmed.ncbi.nlm.nih.gov/33152120/

     

  16. Maeda M, Muraki Y, Kosaka T, Yamada T, Aoki Y, Kaku M, Seki M, Tanabe Y, Fujita N, Niki Y, Morita K, Yanagihara K, Yoshida K, Kawaguchi T.

    Impact of health policy on structural requisites for antimicrobial stewardship: A nationwide survey conducted in Japanese hospitals after enforcing the revised reimbursement system for antimicrobial stewardship programs.

    J Infect Chemother 27(1):1-6,2021. doi: 10.1016/j.jiac.2020.09.015.

    https://pubmed.ncbi.nlm.nih.gov/33008739/

     

  17. Sakata K, Yasuoka H, Yoshimoto K, Takeuchi T.

    Refractory IgG4-related Pleural Disease with Chylothorax: A Case Report and Literature Review.

    Intern Med Online ahead of print,2021.  doi: 10.1093/rheumatology/keaa312.

    https://pubmed.ncbi.nlm.nih.gov/32743653/

     

  18. Shichijo T, Maruyama D, Yamauchi N, Maeshima AM, Sugano M, Yuda S, Tajima K, Kurihara H, Shimada K, Suzuki T, Toyoda K, Makita S, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Taniguchi H, Minami Y, Izutsu K and Tobinai K.

    Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma.

    Cancer Med 9(23): 8864-8874. doi: 10.1002/cam4.3501. Epub 2020 Oct 6.

    https://pubmed.ncbi.nlm.nih.gov/33022120/

     

  19. Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

    The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.

    Cancer Med 9(23): 8931-8939,2020. doi: 10.1002/cam4.3516. Epub 2020 Oct 10.

    https://pubmed.ncbi.nlm.nih.gov/33037866/

     

  20. Tanaka A, Ishitsuka Y, Ohta H, Fujimoto A, Yasunaga JI, Matsuoka M.

    Systematic clustering algorithm for chromatin accessibility data and its application to hematopoietic cells.

    PLOS Comput Biol 16(11):e1008422. doi: 10.1371/journal.pcbi.1008422. eCollection 2020 Nov.

    https://pubmed.ncbi.nlm.nih.gov/33253153/

     

  21. Hashiguchi Y, Oda K, Katanoda T, Nosaka K, Jono H and Saito H

    Clinical evaluation of cefotiam in the treatment of bacteremia caused by Escherichia coli, Klebsiella species, and Proteus mirabilis: A retrospective study.

    J Infect Chemother 26(11):1158-1163. doi: 10.1016/j.jiac.2020.06.007. Epub 2020 Aug 20.

    https://pubmed.ncbi.nlm.nih.gov/32828676/

     

  22. Kondo Y, Suzuki K, Inoue Y, Sakata K, Takahashi C, Kaneko Y, Takeuchi T.

    Safety and tolerability of ultrasound-guided synovial needle biopsy in Japanese arthritis patients.

    Mod Rheumatol Online ahead of print. 20:1-9,2020. doi: 10.1080/14397595.2020.1847754.

    https://pubmed.ncbi.nlm.nih.gov/33155872/

     

     

  23. Kimura Y, Iwanaga E, Iwanaga K, Endo S, Inoue Y, Tokunaga K, Nagahata Y, Masuda K, Kawamoto H, Matsuoka M.

    A regulatory element in the 3′-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia.

    Eur J Haematol. 2020 Nov 16.doi:10.1111/ejh.13551. PMID:33197296

    https://pubmed.ncbi.nlm.nih.gov/33197296/

     

  24. Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K and Tsukasaki K for collaborative Investigators.

    Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.

    Cancer Sci 111(12): 4567-4580. doi: 10.1111/cas.14658. Epub 2020 Oct 21.

    https://pubmed.ncbi.nlm.nih.gov/32976684/

     

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.